Individual Investors Among Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 6.6% Last Week
Individual Investors Among Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 6.6% Last Week
Key Insights
主要见解
- The considerable ownership by individual investors in Zhejiang Garden BiopharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy
- The top 25 shareholders own 48% of the company
- Institutional ownership in Zhejiang Garden BiopharmaceuticalLtd is 13%
- 浙江花园生物制药有限公司个人投资者拥有相当大的所有权,表明他们在管理和业务策略方面共同拥有更大的发言权。
- 该公司前 25 名股东拥有该公司的 48%。
- 浙江花园生物制药有限公司机构持股占比为 13%。
To get a sense of who is truly in control of Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual investors with 51% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
为了了解谁真正掌控了浙江花园生物制药有限公司(SZSE:300401),了解公司的所有权结构至关重要。拥有51%所有权的是个人投资者,他们面临的最大上行潜力(或下行风险)也就是最高的。
As a result, individual investors collectively scored the highest last week as the company hit CN¥6.3b market cap following a 6.6% gain in the stock.
结果,随着股票上涨 6.6%,上周个人投资者集体得分最高,公司市值达到 63 亿元。
In the chart below, we zoom in on the different ownership groups of Zhejiang Garden BiopharmaceuticalLtd.
在下面的图表中,我们放大了浙江花园生物制药有限公司的不同持股群体。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240601/0-94c48ba8679b3cc3aca8834b325061af-0-333872f123899219f6861b1fa577f259.png/big)
What Does The Institutional Ownership Tell Us About Zhejiang Garden BiopharmaceuticalLtd?
机构投资者持有浙江花园生物制药有限公司的股份数量告诉我们什么?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。
As you can see, institutional investors have a fair amount of stake in Zhejiang Garden BiopharmaceuticalLtd. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Zhejiang Garden BiopharmaceuticalLtd's earnings history below. Of course, the future is what really matters.
正如您所看到的,机构投资者在浙江花园生物制药有限公司拥有相当大的股份。这可能表明公司在投资界享有一定的信誉度。但是,最好不要只依赖于所谓的机构投资者确认。他们有时也会出错。如果多家机构同时改变他们对一只股票的看法,您可能会看到股价快速下跌。因此,值得查看浙江花园生物制药有限公司以下的盈利历史。当然,未来才是真正重要的。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240601/0-94c48ba8679b3cc3aca8834b325061af-1-0ed4e3e04661a7c118625db602ebb418.png/big)
Zhejiang Garden BiopharmaceuticalLtd is not owned by hedge funds. Zhejiang Xiangyun Technology Co., Ltd. is currently the company's largest shareholder with 27% of shares outstanding. In comparison, the second and third largest shareholders hold about 3.9% and 3.1% of the stock. Furthermore, CEO Huanzheng Ma is the owner of 0.7% of the company's shares.
浙江花园生物制药有限公司未被对冲基金持有。浙江湘云科技股份有限公司是目前公司持股的最大股东,持股量占比达到 27%。相比之下,第二和第三大股东持股约为股票的 3.9% 和 3.1%。此外,马焕争总裁是公司股份的持有人之一,持有公司 0.7% 的股份。
A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
对我们的所有权数据进行更深入的研究表明,前25名股东的持股总额不到注册表的一半,表明有一个小股东的大群体,其中没有单个股东拥有多数股份。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
尽管我们需要研究一个公司的机构所有权数据是有道理的,但也需要研究分析师的情绪来了解市场趋势。我们目前没有发现任何关于该股票的分析师报道,所以该公司可能不受广泛持有。
Insider Ownership Of Zhejiang Garden BiopharmaceuticalLtd
浙江花园生物制药有限公司内部持有股权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
内部人员的定义在不同国家之间可能略有不同,但董事会成员始终计数。公司管理层回答董事会,在此应代表股东利益。值得注意的是,有时高级管理人员也在董事会上。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
Shareholders would probably be interested to learn that insiders own shares in Zhejiang Garden Biopharmaceutical Co.,Ltd.. In their own names, insiders own CN¥373m worth of stock in the CN¥6.3b company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.
股东可能会有兴趣了解,浙江花园生物制药有限公司的内部股东拥有该公司的股份。内部股东以其自有名义拥有价值 CNY 3.73 亿的股票,占该 CNY 6.3 亿公司的股份。有人会说,这表明股东和董事会的利益一致。但值得检查的是,这些内部股东是否一直在抛售股票。
General Public Ownership
一般大众所有权
The general public -- including retail investors -- own 51% of Zhejiang Garden BiopharmaceuticalLtd. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
普通公众,包括散户投资者,在浙江花园生物制药有限公司中拥有其 51% 的股份。这样持有的规模给了来自普通公众的投资者一些集体力量。他们可以影响关于高管薪酬、股息政策和拟议的业务收购方面的决定。
Private Company Ownership
私有公司的所有权
We can see that Private Companies own 28%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
我们可以看到,私有公司持有股份总数的 28%。从单独这个事实很难得出任何结论,因此了解拥有这些私有公司的人是值得的。有时,公司内部人员或其他相关方可能通过单独的私有公司持有上市公司的股份。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should learn about the 2 warning signs we've spotted with Zhejiang Garden BiopharmaceuticalLtd (including 1 which is concerning) .
虽然考虑拥有一家公司的不同群体是值得的,但有其他更重要的因素。为此,您应该了解我们发现的2个警告信号(包括1个令人担忧的信号)的浙江花园生物制药有限公司。
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
如果您更愿意查看另一家具有潜在更强财务状况的公司,请不要错过这份由强大财务数据支撑的有趣公司的免费列表。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。